TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30217671
Drug: Trabectedin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin and olaparib combination treatment
Study: 30219274
Drug: Immunocryosurgery (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocryosurgery (5% imiquimod cream daily for five weeks and cryosurgery on day fourteen)
Study: 30219367
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine in pregnant women
Study: 30219367
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine in nonpregnant women
Study: 30219367
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine in pregnant women and nonpregnant women
Study: 30219858
Drug: l-carnitine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine treatment
Study: 30219858
Drug: no l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: no l-carnitine treatment
Study: 30221011
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and sildenafil (100 mg by mouth daily during therapy, three times daily on the day of doxorubicin)
Study: 30221011
Drug: Standard doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doxorubicin chemotherapy alone
Study: 30221150
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg EOW
Study: 30222972
Drug: EUS-guided photodynamic
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided photodynamic therapy (PDT) with intravenous porfimer sodium followed by EUS-PDT
Study: 30223771
Drug: DelApp smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DelApp smartphone application for assessing inattention in delirium, administered within 3 hours of reference standard assessment.
Study: 30224193
Drug: Ertugliflozin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (15 mg single oral dose)
Study: 30224284
Drug: Metformin, pioglitazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, pioglitazone, and lifestyle therapy
Study: 30224284
Drug: Metformin, pioglitazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, pioglitazone, GLP-1 receptor agonist, and lifestyle therapy
Study: 30224284
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy only
Study: 30224322
Drug: No neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neuromuscular blocking agents
Study: 30224333
Drug: Limbr mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limbr mobile phone app suite including daily visual self-reports, rehabilitation video tutorials, passive activity-level measurement, and chat-based health coaching.
Study: 30224333
Drug: Your Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Your Activities of Daily Living module
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets prescribed
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets for musculoskeletal pain
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets for fracture
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets for renal colic or abdominal pain
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets for other pain conditions
Study: 30224393
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg tablets for first 3 days
Study: 30224926
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine ICH-012 (8 herbal medicines including Hirudo and Tabanus)
Study: 30224926
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine ICH-012
Study: 30225601
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with gemcitabine (GEM) 1000 mg/m² for three cycles followed by gemcitabine-erlotinib and radiotherapy
Study: 30225844
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral immunotherapy (OIT) with biweekly dose step-up until reaching maximum maintenance dose (MMD) of 5000 mg peanut protein or individual maintenance dose (IMD).
Study: 30225844
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral immunotherapy (OIT)
Study: 30227072
Drug: MEDI-551, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551, an anti-CD 19 B-cell depleting monoclonal antibody, administered for up to 197 days
Study: 30227856
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy at month 3
Study: 30227856
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy at month 1
Study: 30227856
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy at baseline
Study: 30227886
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg tremelimumab at 90 day intervals
Study: 30227893
Drug: brachyury-targeted antitumor
Normalized name: BN-Brachyury vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: brachyury-targeted antitumor vaccine, TGF-β TRAP/anti-PD-L1 antibody, IL-15 agonist, IDO1 inhibitor
Study: 30228904
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of clarithromycin treatment
Study: 30229280
Drug: CT-P13 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 at a starting dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks up to week 46, with increased dose of 1.5 mg/kg for inadequate response from week 14 to week 46.
Study: 30229280
Drug: CT-P13 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 treatment
Study: 30230263
Drug: Inhaled batefenterol
Normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled batefenterol
Study: 30230947
Drug: JE-CV booster
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV booster dose in children
Study: 30230947
Drug: JE-CV single
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV single dose primary vaccination in toddlers
Study: 30231665
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg [14C]-MT-1303
Study: 30231854
Drug: MRI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI and CTC assessments during radiation therapy
Study: 30231854
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CTCs and MRI
Study: 30232146
Drug: Selective Indoleamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003
Study: 30232224
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg twice daily for 7 days every 21 days
Study: 30232558
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg orally once daily until disease progression or unacceptable toxicity
Study: 30232616
Drug: Intraoperative probe-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative probe-based confocal laser endomicroscopy (pCLE) with near-infrared illumination and indocyanine green as contrast agent.
Study: 30233140
Drug: nimesulide/pantoprazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide/pantoprazole (100 mg/20 mg) twice daily for 14 days
Study: 30233140
Drug: naproxen/esomeprazole magnesium
Normalized name: naproxen/esomeprazole magnesium 375 mg-20 mg ORAL TABLET,IMMEDIATE,DELAY RELEASE,BIPHASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen/esomeprazole magnesium (500 mg/20 mg) twice daily for 14 days
Study: 30233802
Drug: Pirfenidone 801
Normalized name: pirfenidone 801 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone 801 mg three times daily for 24 weeks
Study: 30233808
Drug: Salbutamol (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (900 µg)
Study: 30234000
Drug: Fitbit-Plus (activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitbit-Plus (activity trackers + weekly emails)
Study: 30234419
Drug: HAT TRICK
Normalized name: hATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT TRICK program (12 weekly sessions promoting healthy eating, active living, and social connectedness)
Study: 30234617
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (APDs)
Study: 30235235
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil 10 mg
Study: 30235940
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence measured by time-to-refill
Study: 30236025
Drug: α-1 antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-1 antitrypsin (AAT) therapy, administered as multiple repeated infusions (up to 36) over a long-term period (up to 5 years)
Study: 30236252
Drug: Intraoperative ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ventilation with high tidal volume (8.8 ml/kg) and low PEEP, without recruitment manoeuvres.
Study: 30239252
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate liposome injection (VSLI) 2.25 mg/m²
Study: 30239559
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium fiber (median dose of ∼10.2 g)
Study: 30240327
Drug: Lurbinectedin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm A (BRCA1/2 mutated)
Study: 30240327
Drug: Lurbinectedin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm B (unselected)
Study: 30240327
Drug: Lurbinectedin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in patients with BRCA2 mutations
Study: 30240471
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 1200 mg daily for 6 months
Study: 30240852
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg, orally once daily)
Study: 30240852
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care EGFR TKI (gefitinib 250 mg or erlotinib 150 mg, orally once daily)
Study: 30240937
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily for 16 weeks
Study: 30240937
Drug: Galcanezumab 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 5, 50, 120, and 300 mg subcutaneously every 4 weeks, twice
Study: 30241271
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine equivalents prescribed (30 mg median daily dose for morphine and tramadol).
Study: 30241562
Drug: Xue-Fu-Zhu-Yu Capsule
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xue-Fu-Zhu-Yu Capsule (XFZYC)
Study: 30242747
Drug: Sedation according
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation according to an algorithm promoting alternatives to continuous infusion of midazolam or propofol (intervention group)
Study: 30243299
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 patients without treatment)
Study: 30243418
Drug: Buprenorphine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (various formulations: oral, injection, implant)
Study: 30243418
Drug: Daily buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily buprenorphine formulations (tablet or film)
Study: 30243418
Drug: Weekly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly or monthly injection
Study: 30243418
Drug: Bi-annual implant
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-annual implant
Study: 30243418
Drug: Past buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past buprenorphine prescription
Study: 30243800
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with Tremelimumab
Study: 30244613
Drug: Brexpiprazole as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole as adjunctive treatment
Study: 30245163
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) of nucleus accumbens (NAc) and anterior limb of the internal capsule (ALIC)
Study: 30249277
Drug: Vismodegib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (150 mg/day orally) and Ruxolitinib (15 or 20 mg orally twice daily)
Study: 30250733
Drug: Endotoxin core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endotoxin core antibody levels (EndoCAb)
Study: 30250733
Drug: Staphylococcal antibody
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staphylococcal antibody levels
Study: 30250733
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to varicella
Study: 30251145
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor excision circle (TREC) assay
Study: 30252856
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin at a dose of 200 micrograms per kilogram administered on day 1 and day 8
Study: 30253804
Drug: AMG 228
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 228 (1200 mg, administered intravenously every 3 weeks)
Study: 30253804
Drug: AMG 228
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 228 (180-1200 mg, administered intravenously every 3 weeks)
Study: 30253804
Drug: AMG 228
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 228 (doses > 360 mg, administered intravenously every 3 weeks)
Study: 30253804
Drug: AMG 228
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 228 (monotherapy)
Study: 30254130
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg/d
Study: 30254130
Drug: Ibrutinib 280
Normalized name: ibrutinib 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 280 mg/d
Study: 30254130
Drug: Ibrutinib 140
Normalized name: ibrutinib 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 140 mg/d
Study: 30254130
Drug: Ibrutinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (all doses)
Study: 30255476
Drug: Torasemide monotherapy
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide monotherapy (control group, n=20)
Study: 30256541
Drug: Gedatolisib (89
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gedatolisib (89 mg, intravenous infusion)
Study: 30256893
Drug: Lipid-rich test
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-rich test meal containing 20 mg [13C-10]-β-carotene
Study: 30256905
Drug: Recombinant Zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Zoster Vaccine (RZV)
Study: 30257076
Drug: Lean-body-weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean-body-weight-based dosing of pantoprazole (1.2 mg/kg)
Study: 30258442
Drug: Low-Dose Mycophenolate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Mycophenolate Mofetil
Study: 30258648
Drug: Thiamine 500
Normalized name: thiamine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 500 mg oral capsule once daily for 3 months
Study: 30258648
Drug: Thiamine 500
Normalized name: thiamine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 500 mg oral capsule once daily
Study: 30260396
Drug: Insulin-modified frequently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-modified frequently sampled intravenous glucose test (IM-FSIGT)
Study: 30260412
Drug: Fidaxomicin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin, 200 mg twice daily for 10 days
Study: 30260415
Drug: Propofol infusions
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusions (10 sessions, dosed to suppress EEG activity for 15 minutes)
Study: 30260415
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (20 patients)
Study: 30261236
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (within PCI)
Study: 30262659
Drug: Pomalidomide (POM)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide (POM) 5 mg daily for 21 days every 28 days and Dexamethasone (DEX) 40 mg orally every week
Study: 30263228
Drug: Schizophrenia Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schizophrenia Oral Health Profile (SOHP) questionnaire
Study: 30264504
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy for advanced or metastatic NSCLC
Study: 30264864
Drug: Eliglustat tartrate
Normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eliglustat tartrate 50 or 100 mg twice daily for 8 years
Study: 30267561
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy Oncology Group (RTOG) contouring guidelines
Study: 30268101
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line TB therapy
Study: 30268483
Drug: lumretuzumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumretuzumab (monoclonal anti-HER3 antibody) in combination with erlotinib
Study: 30269073
Drug: Nurse-led monitoring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led monitoring using the structured adverse drug reaction (ADRe) profile
Study: 30270406
Drug: Meropenem-vaborbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days)
Study: 30271191
Drug: Duloxetine (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40-60 mg/day)
Study: 30271191
Drug: Pregabalin (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300-600 mg/day)
Study: 30274768
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure therapy (CPAP) used by 96% of patients with 68% total adherence.
Study: 30274980
Drug: Matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched treatment based on genomic profile
Study: 30275092
Drug: Intravenous Plazomicin
Normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Plazomicin
Study: 30277031
Drug: Counselor-initiated or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselor-initiated or self-paced intervention promoting daily self-weighing
Study: 30277089
Drug: Lenalidomide (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (target 25mg daily) plus dexamethasone for 18 cycles
Study: 30277094
Drug: Plecanatide, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide, dosage and duration not specified
Study: 30278378
Drug: Afatinib 30
Normalized name: afatinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 30 mg/day plus cetuximab 250 mg/m2
Study: 30280586
Drug: ChonDux hydrogel
Normalized name: Chondrus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChonDux hydrogel scaffold implantation in combination with microfracture
Study: 30280905
Drug: AD+HIV (treatment-naive
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD+HIV (treatment-naive HIV diagnosis)
Study: 30280906
Drug: Baseline 25-hydroxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline 25-hydroxy vitamin D <20 ng/mL
Study: 30281207
Drug: Post-acute physical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-acute physical therapy interventions
Study: 30282468
Drug: Home Blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Blood Pressure Monitoring (HBPM) users; racial comparison of treatment intensification.
Study: 30282468
Drug: Home Blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Blood Pressure Monitoring (HBPM) users; gender comparison of treatment intensification.
Study: 30282673
Drug: ROTEM (EXTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTEM (EXTEM ML)
Study: 30282677
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine (ADASUVE) 10 mg self-administered